Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGL-2086 + resmetirom
- Development stage
- Unknown
- Lead developer
- Madrigal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MGL-2086 + resmetirom is an oral combination therapy being developed by Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The combination consists of MGL-2086, a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, and resmetirom, a selective thyroid hormone receptor-beta (THR-β) agonist. By targeting both the GLP-1 and THR-β pathways, the therapy aims to provide synergistic effects on metabolic health, weight loss, and hepatic fat reduction, addressing the underlying drivers of MASH. It is currently in Phase 1 clinical development.
- Other names
- MGL-2086/resmetirom combination
02
Targets
Beyond the preview
Go deeper on MGL-2086 + resmetirom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGL-2086 + resmetirom.